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Abstract 
Background: In response to increasing resistance to anti-malarial drugs, Senegal adopted artemisinin-based combi-
nation therapy (ACT) as the first-line treatment for uncomplicated malaria in 2006. However, resistance of Plasmodium 
falciparum parasites to artemisinin derivatives, characterized by delayed parasite clearance after treatment with ACT 
or artesunate monotherapy, has recently emerged and rapidly spread in Southeast Asia. After 10 years of stability with 
rates ranging from 5.6 to 11.8%, the prevalence of parasites with reduced susceptibility in vitro to monodesethyla-
modiaquine, the active metabolite of an ACT partner drug, increased to 30.6% in 2014 in Dakar. Additionally, after a 
decrease of the in vitro chloroquine resistance in Dakar in 2009–2011, the prevalence of parasites that showed in vitro 
chloroquine resistance increased again to approximately 50% in Dakar since 2013. The aim of this study was to follow 
the evolution of the susceptibility to ACT partners and other anti-malarial drugs in 2015 in Dakar. An in vitro test is the 
only method currently available to provide an early indication of resistance to ACT partners.
Results: Thirty-two P. falciparum isolates collected in 2015 in Dakar were analysed using a standard ex vivo assay 
based on an HRP2 ELISA. The prevalence of P. falciparum parasites with reduced susceptibility in vitro to monodeseth-
ylamodiaquine, chloroquine, mefloquine, doxycycline and quinine was 28.1, 46.9, 45.2, 31.2 and 9.7%, respectively. 
None of the parasites were resistant to lumefantrine, piperaquine, pyronaridine, dihydroartemisinin and artesunate. 
These results confirm an increase in the reduced susceptibility to monodesethylamodiaquine observed in 2014 in 
Dakar and the chloroquine resistance observed in 2013. The in vitro resistance seems to be established in Dakar. 
Additionally, the prevalence of parasites with reduced susceptibility to doxycycline has increased two-fold compared 
to 2014.
Conclusions: The establishment of a reduced susceptibility to monodesethylamodiaquine as well as chloroquine 
resistance, and the emergence of a reduced susceptibility to doxycycline are disturbing. The in vitro and in vivo sur-
veillance of anti-malarial drugs must be implemented in Senegal.
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Background
In response to increasing resistance to anti-malarial 
drugs, Senegal adopted an artemisinin-based combi-
nation therapy (ACT) as the first-line treatment for 
uncomplicated malaria in 2006 [1]. However, the resist-
ance of Plasmodium falciparum parasites to artemisinin 
derivatives, characterized by delayed parasite clearance 
after treatment with ACT or artesunate monotherapy, 
has recently emerged and rapidly spread in Southeast 
Asia [2, 3]. No evidence exists for the emergence of arte-
misinin resistance in Senegal. However, active surveil-
lance of temporal trends in the ex  vivo susceptibility to 
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the anti-malarial drugs used as partner drugs in ACT, 
such as monodesethylamodiaquine, the active metabolite 
of amodiaquine (artesunate–amodiaquine), lumefantrine 
(artemether–lumefantrine), piperaquine (dihydroar-
temisinin–piperaquine) or pyronaridine (artesunate–
pyronaridine), is essential. After 10 years of stability with 
rates ranging from 5.6 to 11.8% [4–6], the prevalence of 
parasites with reduced susceptibility to monodesethyla-
modiaquine increased to 30.6% in 2014 in Dakar [7]. The 
prevalence of P. falciparum isolates with reduced sus-
ceptibility to lumefantrine remained low, below 3%, until 
2014 [4–7]. Additionally, after a decrease in the in vitro 
chloroquine resistance in Dakar in 2009–2011 that paral-
leled the withdrawal of chloroquine treatment [4, 5], the 
prevalence of parasites with in  vitro chloroquine resist-
ance increased again to approximately 50% in Dakar 
since 2013 [6, 7]. The emergence and re-emergence of 
parasites with in vitro resistance to monodesethylamodi-
aquine and chloroquine is disturbing.
The aim of this study was to follow the evolution of the 
susceptibility to ACT partners and to other anti-malarial 
drugs in 2015 in Dakar.
Methods
Patients and sample collection
Thirty-two P. falciparum isolates were collected from 
September to November 2015 and analysed using the 
standard in  vitro assay based on HRP2 ELISA at the 
Hôpital Principal of Dakar. Nineteen isolates came from 
patients (59.4%) who were recruited from the emergency 
unit. The remainder came from the Inter-armies Medi-
cal Centre of Dakar (21.9%), the Institut Pasteur of Dakar 
and other departments of the Hôpital Principal of Dakar.
One of the 32 patients was not from Dakar or its dis-
tricts. Two patients had travelled during the previous 
month (one in Senegal and one in Saudi Arabia).
Anti-malarial treatment prior to admission was not 
recorded. At the Inter-armies Medical Centre of Dakar 
and the Institut Pasteur of Dakar, the patients were diag-
nosed only and were not treated. At the Hôpital Principal 
of Dakar, the patients were treated with diverse treatment 
protocols (i) quinine (9.5%), (ii) intra-venous artesunate 
followed by artemether–lumefantrine (4.8%), (iii) intra-
venous artesunate in combination with doxycycline fol-
lowed by artemether–lumefantrine–doxycycline (9.5%), 
or (iv) intra-muscular artemether with doxycycline fol-
lowed by artemether–lumefantrine–doxycycline (76.2%). 
All of these patients were successfully cured.
Venous blood samples were collected in Vacutainer® 
ACD tubes (Becton–Dickinson, Rutherford, NJ, USA) 
prior to patient treatment. Thin blood smears were 
stained using a RAL® kit (Réactifs RAL, Paris, France) 
based on eosin and methylene blue and were examined to 
determine the level of P. falciparum parasitemia, which 
ranged from 0.066 to 2.46%. The evaluation of the ex vivo 
susceptibility to anti-malarial drugs was performed using 
the same venous blood samples used for diagnostic 
analysis.
Drugs
Chloroquine, monodesethylamodiaquine, lumefantrine, 
piperaquine, pyronaridine, quinine, mefloquine, dihy-
droartemisinin, artesunate and doxycycline were distrib-
uted into 96-well plates as previously described [7]. The 
batches of the plates were validated on the chloroquine-
resistant W2 strain (Indochina) (MR4, Virginia, USA). 
The clonality of this strain was regularly verified in our 
laboratory and by an independent laboratory from the 
Worldwide Antimalarial Resistance Network (WWARN) 
using PCR genotyping of the polymorphic genetic mark-
ers msp1 and msp2 and microsatellite loci [8, 9].
Ex vivo assay
The susceptibility of P. falciparum was evaluated using 
the ex  vivo assay based on HRP2 ELISA as previously 
described [7]. The threshold values for the reduced 
in vitro susceptibility or resistance were the following: 61, 
115, 135, 60, 12, 12, 77, 611, 30, and 37 µM for monode-
sethylamodiaquine, lumefantrine, piperaquine, pyrona-
ridine, dihydroartemisinin, artesunate, chloroquine, 
quinine, mefloquine and doxycycline, respectively [4, 10].
Statistical analysis
The IC50 values were expressed as the geometric mean of 
the IC50 and a confidence interval of 95% (CI 95%) after 
logarithmic transformation. Cross-susceptibility was 
analysed using the Pearson correlation.
Results
The average parameter estimates and the prevalence 
of isolates with ex vivo reduced susceptibility to the ten 
anti-malarial drugs evaluated were shown in Table 1.
The coefficient of correlation was 0.79 (p < 0.0001) for 
chloroquine/monodesethyamodiaquine, 0.32 (p = 0.085) 
for chloroquine/piperaquine and 0.34 (p  =  0.062) for 
monodesethylamodiaquine/piperaquine.
Discussion
In the absence of the strong validation of the associa-
tion between a molecular marker and resistance to the 
components of ACT (lumefantrine, amodiaquine, pipe-
raquine, pyronaridine), an in vitro test is the only method 
currently available to provide an early indication of a 
change in the resistance to ACT partner drugs. Temporal 
surveillance of the in  vitro susceptibility from the same 
site using identical or comparative methodology is the 
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most suitable method to detect emerging and spread-
ing resistance. Additionally, an in  vitro test is the only 
method to assess cross-resistance between antimalarial 
drugs.
In the absence of standardized in  vitro and ex  vivo 
tests, the validation of the batches of plates and of a 
method that uses a P. falciparum strain (regular controls 
of clonality) is essential.
These in vitro and ex vivo tests were the only approach 
to compare results from year to year, among sites or 
laboratories. The in vitro effects, the IC50 values and the 
threshold for in  vitro resistance depend on the method 
used. The methodology (i.e., an isotopic test versus an 
immunoenzymatic test), gas conditions (i.e., O2 and CO2 
and the incubation time are conditions that may affect 
the in vitro effects and the IC50 values [11–15].
The same methodology has been used in our studies 
since 2013. The results for the susceptibility of the W2 
clone to the different anti-malarial drugs tested during 
the last 6 years allow a comparison of the year over year 
data.
The prevalence of P. falciparum parasites with reduced 
susceptibility to monodesethylamodiaquine was 28.1% 
in Dakar in 2015, which confirms the increase observed 
in 2014 (from 5.6% in 2013 to 30.6% in 2014) (p = 0.045 
between 2013 and 2015) [6, 7]. The geometric means 
were comparable in 2014 and 2015 (25.3 and 28.9  nM, 
respectively, p  =  0.517, Welch two sample t test). A 
three-fold increase was observed since 2013 (geometric 
mean, 9.8  nM [95% confidence interval, 5.5–17.4]) [6]. 
A reduced susceptibility to monodesethylamodiaquine 
seems to be established in Dakar since 2014. These data 
are consistent with previous data from Thies, which 
showed changes in the response to the drug amodi-
aquine. Specifically, the P. falciparum parasites became 
less susceptible to amodiaquine between 2008 and 2011 
[16]. Susceptibility to monodesethylamodiaquine must 
be monitored in Senegal. Reduced susceptibility in vitro 
is an early warning of impeding resistance. The latest 
published clinical study on artesunate–amodiaquine in 
Senegal dated from 2012 [17]. Artesunate–amodiaquine 
was highly effective with an adequate clinical and parasi-
tological response of 99.27% at day 42.
The persistence of the increase of reduced in  vitro 
susceptibility to monodesethylamodiaquine could be 
explained by the use of artesunate–amodiaquine as the 
treatment for uncomplicated malaria. The use of this 
therapy could generate the emergence of parasites resist-
ant to amodiaquine and to monodesethylamodiaquine 
[18]. Secondarily, cross-resistance (r = 0.79, p < 0.0001) 
between monodesethylamodiaquine and chloro-
quine may be the cause of the resistance or reduced 
Table 1 Ex vivo susceptibility to standard anti-malarial drugs of 32 Plasmodium falciparum isolates from Dakar collected 
from September 2014 to November 2015. The results were compared to the P. falciparum W2 clone tested under the same 
conditions
CI 95% confident interval 95%
The W2 clone IC50 means are the results of four independent experiments
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susceptibility to both monodesethylamodiaquine and 
chloroquine [4, 19]. This phenomenon of cross-resistance 
could explain the increased in vitro resistance to chloro-
quine, which is no longer used in Senegal. However, an 
increase of chloroquine resistance was observed earlier 
than for monodesethylamodiaquine [6]. In fact, after a 
decrease of in  vitro chloroquine resistance in Dakar in 
2009–2011 that paralleled the withdrawal of chloroquine 
treatment [4, 5], the prevalence of parasites resistant 
in vitro to chloroquine increased again to approximately 
50% in Dakar since 2013 [6, 7]. The results of 2015 con-
firmed this increase, which nevertheless remained sta-
ble (46.9%). This situation has not only been observed 
in Dakar. The in  vitro susceptibility to chloroquine 
increased significantly between 2008 and 2011 in Thies 
[16] as well. Additionally, the prevalence of the mutation 
K76T in the P. falciparum chloroquine resistance trans-
porter gene (pfcrt) increased again to 60% in 2006–2009 
in Pikine (a suburb of Dakar) after a sharp decrease due 
to the cessation of chloroquine use [20].
The second ACT recommended for uncompli-
cated malaria treatment in Senegal is a combination 
of artemether–lumefantrine. In 2015, no isolate with 
reduced in  vitro susceptibility to lumefantrine in Dakar 
was known. Since the introduction of ACT in Senegal, 
the prevalence of P. falciparum isolates with reduced 
susceptibility to lumefantrine remained low, below 3%, 
in Dakar [4–7]. Lumefantrine did not show significant 
cross-resistance with the other standard anti-malarial 
drugs [21], and this result is consistent with clinical out-
comes. All the patients in this study, who were treated by 
artemether–lumefantrine–doxycycline after artesunate, 
artesunate–doxycycline or artemether–doxycycline, were 
successfully cured. The artemether–lumefantrine combi-
nation was highly effective with an adequate clinical and 
parasitological response of 99.2% at day 42 in suburbs of 
Dakar in 2010–2011 and 100% in 2012–2013 [17, 22].
The dihydroartemisinin–piperaquine combination has 
been recently introduced in Senegal as a second-line for 
the treatment of uncomplicated malaria. In 2015, no iso-
late with reduced in vitro susceptibility to piperaquine was 
observed in Dakar. The geometric means were compara-
ble between 2013 and 2015 (32.2 nM in 2013, 34.5 in 2014 
and 36.5 in 2015). Additionally, piperaquine did not show 
in  vitro cross-resistance with chloroquine and monode-
sethylamodiaquine in isolates collected in Dakar (r = 0.32, 
p = 0.085 and r = 0.34, p = 0.062, respectively). The pipe-
raquine in vitro susceptibility was not associated with the 
pfcrt K76T mutation involved in chloroquine resistance 
[23]. The dihydroartemisinin–piperaquine combination 
was highly effective, with an adequate clinical and para-
sitological response of 99.1% at day 42 in the suburbs of 
Dakar in 2010–2011 and 100% in 2012–2013 [17, 22].
Pyronaridine–artesunate, the most recent ACT, is cur-
rently under development for treatment of uncompli-
cated malaria. In 2015, no isolate with reduced in  vitro 
susceptibility to pyronaridine was detected in Dakar. The 
geometric mean in 2015 in Dakar (8.72 nM) was interme-
diate between those observed in 2013 in Dakar (5.8 nM) 
or in Dielmo, in southeastern Senegal, in 1996 and 1997 
(3.8 and 4.5  nM) and in 2014 in Dakar (10.5  nM) [6, 7, 
24, 25]. However, a decrease in pyronaridine susceptibil-
ity is feared in the future due to the association of in vitro 
reduced pyronaridine susceptibility with the pfcrt K76T 
mutation [26]. No clinical data on artesunate–pyronari-
dine therapy are available from Senegal.
In 2015, no isolates with reduced in  vitro susceptibil-
ity to dihydroartemisinin and to artesunate was found in 
Dakar. These results are consistent with those observed 
in previous studies in Dakar [4–6, 9]. A limitation of the 
present study was the absence of the determination of 
in  vitro susceptibility to artemisinin derivatives by the 
ring survival test, which is a better indicator of in  vitro 
artemisinin resistance. Clinical resistance to artemisinin 
was manifested by an increase in the ring-stage survival 
rate after contact with artemisinin [27–29].
Three P. falciparum isolates (9.7%) showed reduced 
in  vitro susceptibility to quinine. This prevalence is 
slightly above that observed in Senegal for 15 years (2.8 
to 6%) [4–7, 9, 30]. The two patients treated with quinine 
were successfully cured. Quinine is currently used less 
and less in Senegal in favour of intra-venous artesunate 
or an intra-muscular artemether injection.
Since 2009, the increase of the prevalence of parasites 
with reduced in vitro susceptibility to mefloquine has sta-
bilized to approximately 50% [4–7]. Mefloquine is rarely, 
if ever, used in Senegal.
Data on the in  vitro susceptibility to doxycycline are 
disturbing. Since 2010, the prevalence of P. falcipa-
rum isolates with reduced susceptibility to doxycycline 
has gradually increased (10.3% in 2010 and 16.7% in 
2014), and it doubled in 2015 (31.2%) [5, 7]. Addition-
ally, the geometric mean of the doxycycline IC50 in 2015 
(25.7 µM) increased by a factor 2–3 in comparison with 
2009, 2010 and 2014 (9.2, 11.6 and 8.5 µM, respectively) 
[4, 5, 7]. These changes must be monitored because 
doxycycline is used in combination with artesunate and 
artemether in the Hôpital Principal of Dakar.
Conclusion
The establishment of reduced in  vitro susceptibility 
to monodesethylamodiaquine and chloroquine resist-
ance as well as the emergence of reduced susceptibility 
to doxycycline are disturbing. A limitation of this study 
was the low number of P. falciparum isolates tested. 
In  vitro and in  vivo surveillance of anti-malarial drugs 
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must be implemented. The reduced in  vitro susceptibil-
ity to monodesethylamodiaquine and doxycycline may 
quickly impact the clinical efficacy of the artemisinin 
combinations used in the Hôpital Principal of Dakar and 
in Senegal. In this context, only the artemisinin deriva-
tives would be effective, similar to monotherapy. How-
ever, resistance of P. falciparum parasites to artemisinin 
derivatives, characterized by delayed parasite clearance 
after treatment with artesunate monotherapy or ACT, 
has recently emerged and rapidly spread in Southeast 
Asia, but has not had an impact up to now in Africa.
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